Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin and nutraceuticals for cardiovascular risk markers
ACTRN12618000692235Phase 3Withdrawn
- Sponsor
- Curtin University
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of atorvastatin in cardiac morbidity (4 arms), sponsored by Curtin University. Primary endpoints: Low density lipoprotein cholesterol and Vascular function. Planned start May 2018; status: withdrawn.
02
Drugs
atorvastatin
03
Conditions
cardiac morbidity
Beyond the preview
Go deeper on ACTRN12618000692235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000692235.